A new study indicates that the administration of sivelestat, a neutrophil elastase inhibitor, may significantly reduce the incidence of acute respiratory distress syndrome (ARDS) and associated mortality following cardiovascular surgery. The findings, stemming from a randomized clinical trial, offer a potential new avenue for mitigating a serious complication that frequently arises after complex cardiac procedures.
ARDS represents a substantial challenge in post-operative cardiac care, often leading to prolonged hospital stays, increased healthcare costs, and a heightened risk of death. Researchers have been exploring various strategies to prevent or lessen the severity of ARDS, and sivelestat has emerged as a promising candidate due to its anti-inflammatory properties. This recent research provides stronger evidence supporting its potential benefits.
Sivelestat’s Impact on Post-Operative ARDS
The single-center, randomized, placebo-controlled clinical trial, conducted at a tertiary care academic medical center in China, enrolled 424 patients undergoing cardiovascular surgery between February 15, 2024, and April 16, 2025. Participants included individuals scheduled for a range of procedures, including coronary artery bypass grafting, valve surgeries, ascending aortic reconstruction, congenital heart defect repairs, and cardiac tumor resections. Patients were randomly assigned to receive either continuous intravenous sivelestat (0.2 mg/kg/h) initiated immediately upon admission to the intensive care unit (ICU) postoperatively, continuing for up to seven days or until ICU discharge, or a volume-matched placebo.
The primary outcome measured was the incidence of ARDS. Secondary outcomes included serial measurements of inflammatory biomarkers – interleukin 6, interleukin 8, tumor necrosis factor, systemic immune-inflammation index, and serum neutrophil elastase – taken on postoperative days 1, 3, 5, and 7. Researchers also tracked ARDS-related clinical outcomes such as death, pneumonia, and the require for reintubation. Analysis was performed using an intention-to-treat basis.
Study Details and Findings
The study focused on evaluating whether sivelestat could reduce the inflammatory response triggered by cardiopulmonary bypass and subsequent cardiac surgery. Neutrophil elastase, an enzyme released by neutrophils, plays a key role in this inflammatory process and can contribute to lung injury. Sivelestat works by specifically inhibiting this enzyme.
While detailed results are still being analyzed and disseminated, initial findings suggest a positive correlation between sivelestat administration and a reduction in ARDS incidence. Further research is underway to fully understand the magnitude of this effect and to identify which patient populations might benefit most from this intervention. A systematic review and meta-analysis, published in February 2026, aims to comprehensively evaluate sivelestat sodium’s efficacy in ARDS/ALI patients by including both English and Japanese clinical literature, addressing potential language bias and differing clinical practices .
Prophylactic Potential and Future Directions
Previous research has indicated that prophylactic administration of sivelestat may be beneficial in reducing the occurrence of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in patients at high risk after elective cardiac surgery . The current study builds upon these earlier observations, providing more robust evidence from a randomized controlled trial.
The potential benefits of sivelestat extend beyond simply reducing ARDS incidence. By mitigating the inflammatory response, the drug may also contribute to improved patient outcomes, including reduced mortality and shorter hospital stays. A trial evaluating sivelestat and ARDS after cardiovascular surgery also confirmed these findings , and a related study published in PubMed highlights the importance of sivelestat as a therapeutic potential in preliminary studies.
Looking ahead, further research is needed to optimize the dosage and duration of sivelestat treatment, as well as to identify biomarkers that can predict which patients are most likely to respond to the therapy. The ongoing systematic review and meta-analysis will play a crucial role in synthesizing the available evidence and informing clinical practice guidelines. The continued investigation of sivelestat represents a significant step forward in the quest to improve outcomes for patients undergoing cardiovascular surgery.
This research offers a promising development in post-operative cardiac care. As studies continue, we can anticipate a clearer understanding of sivelestat’s role in preventing ARDS and improving patient recovery.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on this new research? Share your comments below, and please share this article with your network!
